Eli Lilly has announced that it will provide early access to its experimental obesity treatment retatrutide for a limited group of eligible patients ahead of potential regulatory approval. The decision follows positive Phase 3 clinical trial results that demonstrated substantial weight loss and improvements in blood sugar control, reinforcing expectations that retatrutide could become one of the next major therapies for obesity.
According to Reuters, the early access program is intended for select patients with serious medical needs who may benefit from the investigational treatment before it becomes commercially available, subject to applicable regulations and physician oversight.
